Shares of Exact Sciences Corp. stock slid 7 percent on Tuesday after the Madison company announced a wider loss in its quarterly earnings report along with plans to sell more shares.
The stock closed at $25.15, down $1.88. But at least two analysts issued upbeat notes, reiterating their projections that shares will rise to the mid-$30 range for the maker of the Cologuard non-invasive DNA test for colorectal cancer.
